CARDINAL HEALTH INC CAH

Cardinal Health's strongest current evidence is the April 30, 2026 10-Q: revenue for the three months ended March 31, 2026 increased 11 percent to $60.9 billion, primarily due to branded and specialty pharmaceutical sales growth from existing customers. For the nine months ended March 31, 2026, revenue increased 17 percent to $190.6 billion, with the company pointing to branded and specialty pharmaceutical sales growth from existing and new customers.

The business story is a distribution story first. Cardinal Health sits on the medicine supply rail, and the supplied filing evidence makes the product link plain: pharma segment revenue for the three months ended March 31, 2026 increased 11 percent to $56.1 billion, primarily due to branded and specialty pharmaceutical sales growth from existing customers. The equity case in this file is therefore not built on a product launch claim; it is built on whether a very large pharmaceutical distribution machine can keep turning sales growth into income, cash and controlled working capital.

The filed financial facts give the report its harder edge. SEC EDGAR filed financials show revenues of $65.63 billion, net income attributable to parent of $467.0 million, operating income of $707.0 million, assets of $58.08 billion, cash and cash equivalents of $2.78 billion, net cash provided by operating activities of $1.66 billion, payments to acquire property, plant and equipment of $239.0 million, inventory of $20.12 billion and stockholders' equity attributable to parent of negative $2.88 billion for the 10-Q period ending December 31, 2025. Diluted earnings per share were $1.88 for the 10-Q period ending September 30, 2025, and diluted weighted average shares outstanding were 237.0 million for the period ending December 31, 2025.

No chart route or price level is supplied in this evidence rail, so this report cannot claim candle behaviour, support, resistance, moving averages or a market reaction. The source route is official filing based: SEC EDGAR, the company's submissions JSON and the companyfacts JSON. That matters because the file can describe the operating mechanism, revenue growth, cash conversion and working capital load, but it cannot pretend to have seen intraday trading.

What changed most clearly is the April 30, 2026 results package: the company filed a 10-Q and an 8-K saying it issued a news release for the quarter ended March 31, 2026, with webcast slides and an audio replay available on the Investors page at ir.cardinalhealth.com. The more recent June 1 SD filing and June 8 Form 144 add to the public filing trail, while the two April 29 Schedule 13G filings show ownership disclosure activity. The rail does not supply guidance, dividend detail, buyback detail, litigation claims, analyst views or a current share price, so those are outside the file rather than missing colour.